Medtronic has completed its acquisition of SPR Therapeutics, a pain management medtech company, for $650 million.
SPR Therapeutics develops percutaneous peripheral nerve stimulation therapies for chronic and acute pain management. Nearly 50 million adults in the U.S. are affected by chronic pain, according to a July 16 news release from Medtronic.
SPR’s Sprint PNS System is cleared by the FDA and provides pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant.
Medtronic expects the acquisition to be minimally dilutive to Medtronic adjusted earnings per share in fiscal year 2027 and neutral to accretive thereafter, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.